PSY8-6 Current status and issues in the management of prostate cancer with BRCA gene mutation

Abstract

Men with a family history of hereditary breast and ovarian cancer syndrome are at increased risk of developing prostate cancer, especially men with germline BRCA2 mutations. Prostate cancer with germline BRCA2 mutations is known to have a younger age of onset, higher grade, and lower survival after curative treatment. In addition, prostate cancer with BRCA2 mutations is characterized by genomic instability and is pathologically associated with intraductal carcinoma of the prostate. Therefore, counseling and prostate-specific antigen testing starting at age 40 should be suggested for men with germline BRCA2 mutations.